Subjective cognitive decline. The first clinical manifestation of Alzheimer’s disease?
Dementia & Neuropsychologia, vol. 10, núm. 3, julio-septiembre, 2016, pp. 170-177
Associação Neurologia Cognitiva e do Comportamento
São Paulo, Brasil

Available in: http://www.redalyc.org/articulo.oa?id=339547442002
Subjective cognitive decline

The first clinical manifestation of Alzheimer’s disease?

Adalberto Studart Neto1, Ricardo Nitrini1

ABSTRACT. Background: Mild cognitive impairment is considered as the first clinical manifestation of Alzheimer’s disease (AD), when the individual exhibits below performance on standardized neuropsychological tests. However, some subjects before having a lower performance on cognitive assessments already have a subjective memory complaint. Objective: A review about subjective cognitive decline, the association with AD biomarkers and risk of conversion to dementia. Methods: We performed a comprehensive non-systematic review on PubMed. The keywords used in the search were terms related to subjective cognitive decline. Results: Subjective cognitive decline is characterized by self-experience of deterioration in cognitive performance not detected objectively through formal neuropsychological testing. However, various terms and definitions have been used in the literature and the lack of a widely accepted concept hampers comparison of studies. Epidemiological data have shown that individuals with subjective cognitive decline are at increased risk of progression to AD dementia. In addition, there is evidence that this group has a higher prevalence of positive biomarkers for amyloidosis and neurodegeneration. However, Alzheimer’s disease is not the only cause of subjective cognitive decline and various other conditions can be associated with subjective memory complaints, such as psychiatric disorders or normal aging. The features suggestive of a neurodegenerative disorder are: onset of decline within the last five years, age at onset above 60 years, associated concerns about decline and confirmation by an informant. Conclusion: These findings support the idea that subjective cognitive complaints may be an early clinical marker that precedes mild cognitive impairment due to Alzheimer’s disease. Key words: subjective cognitive decline, dementia, Alzheimer’s disease, biomarkers.

DECLÍNIO COGNITIVO SUBJETIVO: A PRIMEIRA MANIFESTAÇÃO CLÍNICA DA DOENÇA DE ALZHEIMER

RESUMO. Introdução: O comprometimento cognitivo leve é considerado como a primeira manifestação clínica da doença de Alzheimer, quando o indivíduo exibe um desempenho abaixo para idade e escolaridade em testes neuropsicológicos padronizados. No entanto, alguns já apresentam uma queixa subjetiva de memória antes de apresentarem alterações cognitivas. Objetivo: Fazer uma revisão sobre o declínio cognitivo subjetivo, a associação com biomarcadores da doença de Alzheimer e o risco de progressão para demência. Métodos: Realizou-se uma revisão não-sistemática no PubMed. As palavras-chave utilizadas na busca foram relacionadas ao declínio cognitivo subjetivo. Resultados: O declínio cognitivo subjetivo é caracterizado por uma autoexperiência da deterioração no desempenho cognitivo não detectado objetivamente por meio de testes neuropsicológicos formais. Todavia, vários termos e definições são utilizados na literatura e a falta de um conceito largamente aceito dificulta uma comparação. Os dados epidemiológicos mostram que indivíduos com declínio cognitivo subjetivo estão em maior risco de progressão para demência. Além disso, há evidências de que este grupo tem maior prevalência de biomarcadores positivos para amiloide e neurodegeração. Porém, a doença de Alzheimer não é a única causa e várias outras condições podem estar associadas, tais como distúrbios psiquiátricos ou o envelhecimento normal. As características sugestivas de uma doença neurodegenerativa são: início nos últimos cinco anos, início acima de 60 anos, estar preocupado com declínio e confirmação por um informante. Conclusão: Estes resultados suportam a ideia de que o declínio cognitivo subjetivo pode ser um marcador clínico precoce que precede comprometimento cognitivo leve devido à doença de Alzheimer. Palavras-chave: declínio cognitivo subjetivo, doença de Alzheimer, biomarcadores.
INTRODUCTION

Currently, the development of disease-modifying treatments for Alzheimer’s disease (AD) targets stages of the disease prior to the dementia syndrome, in which neuronal damage is already irreversible. From the development of biomarkers that allow the detection of β-amyloid peptide, tau protein and neuronal injury, it is known that the AD pathology precedes the onset of dementia by many years.1,2 Consequently, identifying the first manifestation of AD with the aid of biomarkers can enable early diagnosis and therapeutic interventions.

The working group of the National Institute on Aging-Alzheimer’s Association (NIA-AA) has produced new recommendations for the diagnosis of dementia due to Alzheimer’s disease and proposed the concept of AD stages based on the model of the “amyloid cascade”.3 According to this model, the disease runs in a continuous course from the preclinical phase (defined as absence of cognitive decline and presence of positive AD biomarkers) to the mild cognitive impairment stage (decline in at least one cognitive or behavioral domain without functional impairment and the presence of positive biomarker) through to the dementia phase due to Alzheimer’s disease (impairment in at least two cognitive domains with functional decline).1,3,4 Also according to the NIA-AA, the preclinical phase begins with the cerebral amyloidosis stage (deposition of β-amyloid), followed by amyloidosis with neurodegeneration, and finally the subtle cognitive decline stage associated with positive AD biomarkers.1

This subtle cognitive decline is characterized by a self-experience of deterioration in cognitive performance not detected objectively through formal neuropsychological testing.1,3,4 Traditionally, the consensus considered mild cognitive impairment as the first clinical manifestation of the disease, when the individual exhibits below-average age-, gender- and education-adjusted performance on standardized neuropsychological tests.5,6 However, longitudinal studies, especially those using biomarkers, have shown that before having a lower performance on cognitive assessments, subjects already have a subjective memory complaint. The term “subjective cognitive decline” was created to describe this stage prior to mild cognitive impairment.6 This article entailed a non-systematic review on subjective cognitive decline, the association with AD biomarkers and risk of conversion to dementia. This knowledge is critical to understanding the early stages of the disease which can become targets of future earlier therapeutic interventions.

METHODS

We performed a comprehensive literature non-systematic review on PubMed for references published between January 1990 and July 2016. The keywords used in the search were terms and words related to subjective cognitive decline: “subjective memory complaint”, “self-reported memory complaint”, “subjective cognitive impairment” and “subjective cognitive concerns”.5,6,7 Consequently, the lack of a widely accepted concept, a “gold standard”, makes it difficult to compare studies.8,9 A multicenter international working group (Subjective Cognitive Decline Initiative, SCD-I) was created with the objective to standardize terminology for studies and clinical trials.5 This group proposes the use of the term “subjective cognitive decline”. “Subjective” because it refers to individual self-experience, regardless of objective performance on neuropsychological tests. The term “cognitive” rather than “memory” because the first symptoms of Alzheimer’s disease are not restricted only to the memory domain. And finally, “decline” refers to the idea of progressive deterioration or a change from the previous level of functioning and not just an isolated complaint.5,7 Thus, the proposed criteria are: [1] self-experienced persistent decline in cognitive abilities compared with previously normal status and not related to an acute event; and [2] normal performance on standardized cognitive tests (for age, gender and education); while exclusion criteria are: [1] mild cognitive impairment or dementia diagnosis; and [2] decline explained by psychiatric disorders, neurological diseases (except Alzheimer’s disease), other medical disorders, medication or other substance use.5

Several epidemiological studies have shown an increased risk of progression to AD dementia among individuals with subjective cognitive decline.6,10 However, these epidemiological studies differ in the method of evaluation of subjective complaints. While some studies were based on testimonies of participants, other applied standardized questionnaires (as discussed in the following section). Consequently, this difference of methodology impairs in part the comparison between...
Subjective cognitive decline: how can it be identified?

Although several studies have evaluated subjective cognitive decline and its risk of progression to dementia, there is no standard on how the evaluation should be carried out. Ideally, the assessment of subjective cognitive decline in any study must provide balance and not be too sensitive (with high false positive rates) or very specific (and therefore too restrictive). How can we objectively evaluate a subjective complaint?

Several questionnaires and scales have been developed and applied in clinical and epidemiological studies. The most frequent self-reported measures include: Questionnaire AgeCoDe Study, Everyday Cognition scale (E-cog), Memory Functioning Questionnaire (MFQ), Subjective memory decline scale (SMDS), Memory complaint questionnaire (MAC-Q), Memory failures everyday - 30 (MFE - 30), Structured Telephone Interview for Dementia Assessment (STIDA), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) and Subjective Memory Complaints (SMC). These differ in mode of administration, number of items, timeframe referenced by items, cognitive domains reported as complaints and degree of severity.
Some self-reported measures explore only memory complaints, while others evaluate decline in other cognitive abilities. Even among the scales that include memory complaints only, some are generic issues while other measures evaluate specific everyday situations. Another difference is a large variability among questionnaires in relation to response timeframe and subjective perception. Some of these instruments compare current cognitive performance with a few weeks or months ago, while others compare with several years ago or even when younger.²⁷

As previously mentioned, not all subjective memory complaint is due to pre-clinical Alzheimer’s disease. Of other causes, mental disorders are among the most often associated and therefore the evaluation of patients with subjective memory complaint must include a neuropsychiatric inventory. However, even excluding patients who meet criteria for a major psychiatric disorder, symptoms of depression and anxiety or morbid personality traits are fairly frequently observed in epidemiological studies.²⁸⁻²⁹ Thus, in clinical practice, how can it be distinguished whether a cognitive complaint is due to a mental disorder or Alzheimer’s disease in the preclinical stage? For this purpose, some authors have coined the term “subjective cognitive decline plus” whose features increase the likelihood of an underlying neurodegenerative disorder.³⁰⁻³¹ For example, a decline noticed by the patient within a five-year interval increases the probability of preclinical AD. In contrast, complaints in a patient with a history of many years most likely have causes other than AD. Age of onset is also an important feature to distinguish neurological and psychiatric causes. It is more likely for an elderly person than a young adult to have subjective decline due to Alzheimer’s disease. As discussed in the studies cited above, associated concerns with complaint and confirmation of decline by an informant are features that suggest a neurodegenerative cause. In summary, elderly with increased risk of conversion to dementia are those with progressive memory complaint within the last five years, concerns about decline, and whose family members confirm this decline.

Although subjective cognitive decline is defined as a complaint without detectable impairment by standardized neuropsychological tests, a new generation of episodic memory tests has shown utility for the diagnosis of Alzheimer’s preclinical disease with a good correlation with subjective complaint.²⁷⁻³⁰ For example, a task of Short-Term Memory Binding (STMB) has recently been validated and shown to be more sensitive than traditional neuropsychological evaluations in individuals with subjective cognitive decline for diagnosing the pre-clinical stage of Alzheimer’s disease.²⁷ Other tests developed, which have also shown good correlation with subjective cognitive impairment, were the Name Face Associative Memory Exam (FNAME)²⁸ and evaluation of prospective memory.²⁹ Therefore, these are useful tools in the clinical evaluation of patients with subjective cognitive decline, which increases the specificity of the complaint as a marker of preclinical Alzheimer’s disease.

Subjective cognitive decline studies in the Brazilian population. Although an increasingly discussed topic in Cognitive Neurology, there are few studies involving the Brazilian population.³⁰⁻³⁵ Moreover, to date, there are no published Brazilian studies involving AD biomarkers in patients with subjective cognitive decline.

In a community-based study, seventy-one healthy older adults were asked if they had memory complaints, filled out the Memory Complaint Questionnaire (MAC-Q) and underwent a formal test of episodic memory (Rey Auditory Verbal Learning Test - RAVLT). Spontaneous complaints were associated with poor performance on the RAVLT, but not on the MAC-Q.³³ Another study analyzed the presence of memory complaint in 163 subjects without dementia in a forest reserve in the Brazilian Amazon. The study volunteers were submitted to the Mini-Mental State Examination (MMSE), delayed recall from the Brief Cognitive Battery and a questionnaire assessing psychiatric symptoms. Results revealed a positive correlation between the presence of psychiatric symptoms and lower MMSE scores but not delayed recall test scores.³⁴

On the other hand, some studies have shown no correlation between worse performance on cognitive tests and the presence of subjective decline.³⁵⁻³⁶ In one investigation, two groups were compared: one formed by community elders with complaints and another consisting of institutionalized elderly without complaints. No differences were observed between the groups in performance on neuropsychological assessment.³⁵ Similar findings were also obtained in a sample of normal elderly (caregivers of patients with dementia), where there was no statistically significant correlation between subjective complaints and objective cognitive assessment.³⁶

Alzheimer’s disease biomarkers in subjective cognitive decline. In recent years, several studies (such as the “Alzheimer’s Disease Neuroimaging Initiative - ADNI” and “Australian Imaging Biomarkers and Lifestyle study - AIBL”) have been investigating the correlation in vivo of pathologic findings (using biomarkers) with clinical
manifestations of Alzheimer’s disease. Pathological processes most widely investigated through biomarkers are: brain amyloidosis (by decreased β-amyloid peptide in cerebrospinal fluid and PET-CT with positive ligands for β-amyloid - for example Pittsburgh compound B, PiB) and neurodegeneration (by elevated total tau and phosphorylated tau proteins in the cerebrospinal fluid, cortical atrophy on structural magnetic resonance imaging, MRI, and decreased glycolytic metabolism in 18F-fluorodeoxyglucose PET-CT). While there are studies with evidence of increased frequency of amyloidosis and neurodegeneration associated with aging in cognitively normal patients, the presence of amyloidosis in normal elderly is associated with higher rates of progression to mild cognitive impairment and dementia. Consequently, the use of biomarkers attempts to resolve the above question by identifying which individuals with subjective cognitive decline have a higher risk of progressing to an AD dementia stage. Structural MRI, PET-CT with positive ligands for β-amyloid and 18F-fluorodeoxyglucose PET-CT (FDG-PET), are methods that both determine the stage of progression of the disease as well as elucidate the anatomical extent of the disease.

Perrotin et al. compared two groups of normal elderly, one with positive PiB PET-CT and another with negative PiB PET-CT, for subjective cognition and performance on a neuropsychological evaluation. The positive PiB group had a higher frequency of subjective cognitive complaints and worse performance in episodic memory tests. In addition, some anatomical regions of interest showed a positive correlation between increased uptake of radiotracer for amyloid and subjective decline (right medial frontal/anterior cingulate cortex and right precuneus/posterior cingulate cortex). Amariglio et al. applied three subjective cognition questionnaires and a neuropsychological battery in a group of 130 elderly who underwent a PiB-PET. A positive correlation between memory complaints and cortical PiB binding was found. On the other hand, performance on tests of episodic memory and executive functions and cortical PiB binding did not show a statistically significant correlation. The same research group also used PiB-PET, FDG-PET and structural MRI, classifying normal elderly patients into four groups according to status of biomarkers for amyloidosis (Aβ) and neurodegeneration (ND): negative biomarker (Aβ–/ND–), amyloidosis alone (Aβ+ / ND–), amyloidosis plus neurodegeneration (Aβ+/NA+) and suspected non-Alzheimer disease pathophysiology (Aβ–/ND+). Participants filled out a questionnaire for subjective cognitive complaints and the presence of biomarkers correlated with more complaints, especially in the groups with positive Aβ. Similar results were found in a recent longitudinal study. Fifty-eight normal older adults with positive β-amyloid-PET answered a questionnaire of subjective memory decline and underwent neuropsychological assessment. After a follow-up of three years, it was found that individuals with complaints had a higher rate of progression to mild cognitive impairment or dementia (hazard ratio of 5.1) compared to those without complaints. However, two groups did not differ in decline on formal tests of episodic memory. Moreover, the group with complaints had a higher incidence of depressive symptoms and lower left hippocampus volume. However, some studies have failed to demonstrate the relationship between the presence of biomarkers and subjective decline. A prospective study of 289 healthy elderly found no differences between PiB-PET status and presence of subjective memory complaint, although a group with positive PiB-PET showed a moderate decline in working memory and learning. Recently, the development of a PET tracer with high affinity for tau protein has allowed to understand the distribution of tau aggregates in vivo. However, there are still no published studies of tau imaging in normal individuals with subjective memory complaints.

Evidence also points to a correlation between subjective cognitive decline and cortical atrophy on structural MRI, especially in commonly vulnerable regions for Alzheimer disease. In one such study, two hundred and sixty-one healthy middle-age adults were asked whether they had a memory problem. The group with cognitive complaints had significant cortical thinning in the entorhinal, fusiform, posterior cingulate and posterior parietal cortices, as well as reduced amygdala volume. Additionally, this same group showed worse performance on memory tests, even within the normal range. A pattern of gray matter atrophy, similar to that found in Alzheimer’s disease, has been found in a group of 226 subjects with subjective memory disorders in a German study. A cross-sectional study compared hippocampal volume in 47 healthy elderly with memory complaints and 48 normal controls and measured the plasma levels of beta amyloid. Those with subjective complaints showed lower volume in CA1, CA2, dentate gyrus and the molecular layer and had higher levels of beta amyloid. Other neuroimaging methods have also been exploited by several studies on subjective cognitive decline, such as functional magnetic resonance imaging (fMRI) and MRI with diffusion tensor imaging (DTI). In one fMRI study, there was less activation of the right hippocampus in patients with subjective decline during
In a Dutch longitudinal study, A Span... the course of episodic memory testing, despite the fact that test performance was within the normal range.68

And a Japanese study examined the association of white matter connectivity (by performing MRI-DTI) and amyloid deposition (PiB-PET) and compared two groups (one with subjective cognitive impairment and another without complaint). In the end, it was found that individuals with subjective cognitive impairment had reduced functional connectivity between retrosplenial cortex and anterior medial cortical structures.59

Similarly to imaging methods, studies of β-amyloid peptide, total tau and phosphorylated tau proteins in cerebrospinal fluid (CSF) are widely used in investigations of subjective cognitive decline.60-64 In a multicenter cohort, the frequency of individuals with subjective complaint and positive AD biomarkers in CSF was superior to the control group (52% vs. 31%).60 A Spanish longitudinal study followed 149 subjects without dementia (but with subjective cognitive decline or mild cognitive impairment) for five years and found that only 15% of those with pathological CSF remained free of AD dementia. The odds ratio for conversion to dementia was 27.1, demonstrating that an abnormal AD CSF biomarker profile is a powerful predictor for cognitive and functional decline.61 In a Dutch longitudinal study, a sample of 127 volunteers with subjective decline was followed by two years after collection of CSF biomarkers. The study found that a decrease in Aβ CSF was the strongest predictor of progression to mild cognitive impairment and dementia (odds ratio 16).61

In addition to the biomarkers, AD has many other risk factors, but none is better established than the ε4 allele of apolipoprotein E (APOE). There is ample evidence that individuals with subjective cognitive decline have a greater frequency of expression of the allele, especially among those with positive biomarkers.55,66 Samieri et al. compared subjective cognitive decline among APOE ε4 carriers and non-carriers for over six years. The authors concluded that APOE ε4 carriers evolved with faster memory decline.66 In a more recent study, normal elderly with memory complaints were also grouped into APOE ε4 carriers and non-carriers and underwent amyloid PET, FDG PET, structural MRI and CSF biomarker testing. The APOE ε4 carriers had changes in amyloid PET and CSF biomarkers. Therefore, these results indicate an association between the APOE ε4 allele and AD biomarkers in older adults with memory complaints.66

CONCLUSIONS

Several studies have shown that individuals with subjective cognitive decline are at increased risk of progression to AD dementia. According to epidemiological data, the features which increase the likelihood of conversion are: onset of decline within the last five years, age at onset above 60 years, associated concerns about decline and confirmation by an informant. In addition, there is evidence that this group has a higher prevalence of positive biomarkers for amyloidosis and neurodegeneration. Consequently, these findings support the idea that subjective cognitive complaints may be an early clinical marker of pathology and help further understanding on the natural history of Alzheimer’s disease from pre-dementia stages. However, due to lack of consensus on how to define and assess subjective cognitive decline, it is still unclear which characteristics of subjective cognitive decline suggest the preclinical AD stage.

Author contribution. Adalberto Studart Neto contributed to study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript and critical revision of the manuscript for important intellectual content. Ricardo Nitrini contributed drafting of the manuscript and critical revision of the manuscript for important intellectual content.

REFERENCES

of healthy adults with and without subjective cognitive impairment. 


57. Jessen F, Feyen L, Freymann K, et al. Volume reduction of the ento-
rhinal cortex in subjective memory impairment. Neurobiol Aging. 2006;
27(12):1751-1756.
during episodic memory in subjective memory impairment. Arch Gen
the retrosplenial cortex and anterior medial cortical structures relates to
CSF markers of Alzheimer’s disease pathology in patients with subjec-
tive cognitive impairment or mild cognitive impairment in the DESCIRPA
is the best predictor of clinical progression in patients with subjective
decline in memory and executive functions in subjective complaints.
is related to CSF biomarkers of AD in patients with MCI. Neurology.
2015;84(12):1261-1268.
Predict Clinical Evolution in Patients with Subjective Cognitive Decline
2014;10(6):752-759.
biomarkers in older adults with significant memory concern. Alzheimers
Dement. 2015;11(12):1417-1429.